Neighborhood Health Plan RI rituximab Coverage & Prior Auth

Coverage Criteria for Rituximab and Biosimilars (Non‑Oncology/Non‑Hematology)

Initial Therapy

Covered when ALL of the following are met:

Initial universal requirements: Patient screened for HBV infection (HBsAg and anti-HBc) prior to initiating therapy; AND for new starts requesting Rituxan or Riabni, patient has failure or intolerable side effects to Ruxience or Truxima unless the member is currently on Rituxan/Riabni or is a Medicare member who received medication within the past 365 days; AND patient is not on concurrent treatment with another CD20-directed therapy, TNF-inhibitor, IL-inhibitor, biologic response modifier or specified non-biologic agents (e.g., apremilast, abrocitinib, tofacitinib, baricitinib, upadacitinib, deucravacitinib).

From Initial Criteria (policy)

Indication: Rheumatoid arthritis (RA): Adult (≥18 years); documented moderate to severe disease; used in combination with methotrexate unless contraindicated or intolerant; trial and failure of at least a 3-month trial with one oral DMARD; prior trial of at least one preferred TNF antagonist (minimum one self-injectable) for ≥3 months; physician-assessed baseline disease severity with an objective tool; no rituximab in the previous 4 months.

From RA initial criteria

Indication: Pemphigus vulgaris (PV): Diagnosis confirmed by clinical features (lesions/erosions/blisters, Nikolsky sign, characteristic scarring/distribution), histopathologic confirmation by biopsy, and positive direct immunofluorescence (DIF) OR autoantibodies by IIF/ELISA; moderate to severe disease assessed with an objective tool (e.g., PDAI, PSS, ABSIS); other blistering diseases ruled out; used in combination with glucocorticoids.

From PV initial criteria

Indication: Granulomatosis with polyangiitis (GPA) / Microscopic polyangiitis (MPA): Patient aged ≥2 years; used in combination with glucocorticoids.

From GPA/MPA initial criteria

Indication: Multiple sclerosis (MS): Confirmed diagnosis of MS documented by MRI; diagnosis is a relapsing form (relapsing-remitting MS, active secondary progressive MS, or clinically isolated syndrome).

From MS initial criteria

Indication: Autoimmune hemolytic anemia (AIHA): Warm-reactive AIHA refractory to or dependent on glucocorticoids OR cold agglutinin disease with symptomatic anemia, transfusion-dependence, and/or disabling circulatory symptoms.

From AIHA initial criteria

Indication: Systemic lupus erythematosus (SLE): Confirmed SLE with classification score >10 including clinical and immunologic domains; ANA titer >1:80 (IIF) or equivalent at least once; inadequate response to ≥2 standard therapies (e.g., anti-malarials, corticosteroids, immunosuppressives); will not be used with voclosporin (Lupkynis) or anifrolumab (Saphnelo); patient not on other biologics and does not have severe active CNS lupus; moderate to severe active disease defined by PGA >1 AND one of: SLEDAI-2K >6, BILAG-2004 with >2 B scores or ≥1 A score.

From SLE initial criteria

Indication: Lupus nephritis: Active Class III, IV, or V lupus nephritis confirmed by renal biopsy; disease non-responsive or refractory to standard first-line therapy (e.g., mycophenolate, cyclophosphamide, calcineurin inhibitors); used as single agent or add-on with specified immunosuppressives; baseline uPCR, eGFR, or urine protein provided; no severe active CNS lupus; not on other biologics.

From Lupus Nephritis initial criteria

Indication: Myasthenia gravis (MuSK-positive): MuSK-antibody positive disease and refractory to standard first-line therapy (e.g., glucocorticoids, azathioprine, mycophenolate mofetil).

From Myasthenia Gravis initial criteria

Continuation Therapy

Continued coverage when ALL of the following are met:

General continuation requirements: Patient continues to meet the initial criteria and is tolerating treatment without unacceptable toxicity (examples: severe infusion reactions, tumor lysis syndrome, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy, viral hepatitis, serious infections, cardiac arrhythmias, renal toxicity, bowel obstruction/perforation).

From Continuation criteria

RA continuation: Demonstrated disease response versus baseline (e.g., reduction in tender/swollen joint counts, decreased CRP, improved patient global assessment, and/or improvement on disease activity scoring such as DAS28 improvement ≥1.2 or ACR20 ≥20%); dose escalation up to the maximum may be considered if initial response occurred, at least one maintenance dose was given at specified dose/interval, and subsequent loss of response is documented.

From RA continuation criteria

GPA/MPA continuation: Disease control and improvement in signs and symptoms compared to baseline and a decreased frequency of major relapses (reappearance of clinical or laboratory signs of vasculitis activity that could lead to organ failure or be life-threatening).

Initial and continuation coverage criteria

Covered when dosing and indication-specific criteria are met; initial and continuation coverage durations specified.

General coverage timing: Initial coverage duration: 6 months; continuation (renewal) coverage: 6 months unless otherwise stated in continuation criteria. Medicare applicability subject to NCD/LCD per policy.

Accepted dosing regimens: Common regimens include: 1,000 mg IV on days 1 and 15 (may be repeated up to every 24 weeks or more frequently based on clinical evaluation, with maintenance options) OR 375 mg/m² IV once weekly for 4 doses (equivalent induction regimens and maintenance dosing specified per indication).

See dosing/administration sections for indication-specific maintenance, relapse, pediatric adjustments and timing.

Dosing limits by indication (examples): RA: maximum 100 units per dose (1 unit =10 mg) every 14 days x2 doses in an 18-week period. GPA/MPA: induction up to 100 units per dose weekly x4 in a 4-month period; initial maintenance and subsequent maintenance limits specified. Pemphigus vulgaris: initiation up to 100 units weekly x4 in a 12-month period; maintenance/relapse 50 units every 16 weeks. Lupus nephritis & Myasthenia Gravis: up to 100 units per dose every 14 days x2 doses in a 6-month period OR 100 units per dose weekly x4 doses in a 20-week period. MS: 100 units every 14 days x2 doses every 6 months. All other non-oncology indications: 100 units per dose weekly x4 doses in a 6-month period.

Investigational

Not covered/Investigational:

Investigational use: Use at doses or for conditions other than recognized medically accepted indications (as defined by standard compendia or peer-reviewed literature) is considered investigational and is not covered by the plan.

Per policy investigational use statement and dosing limits section

Rituximab and its biosimilars are covered under the medical benefit for non‑oncology/non‑hematology indications only when the plan's specified clinical criteria are met. Use outside these stated guidelines may result in non‑payment unless approved under an exception process. For SLE, the policy excludes use in patients with severe active central nervous system lupus and excludes concomitant use with other biologics and with voclosporin (Lupkynis) or anifrolumab (Saphnelo). For lupus nephritis, coverage requires biopsy‑confirmed Class III, IV, or V disease and excludes patients with severe active CNS lupus or those receiving other biologics; baseline renal protein and function measurements must be provided.

Uses of rituximab that are not recognized as medically accepted indications — including use at doses or for conditions not supported by standard reference compendia or peer‑reviewed literature — are considered investigational. The policy explicitly states that Neighborhood does not provide coverage for therapies when used for investigational purposes.

Prior authorization and adherence to the plan's non‑oncology/non‑hematology guidelines are required for coverage. Use outside the specified guidelines for these indications (without exception approval) may result in non‑payment. Providers should request an exception when an off‑guideline use is clinically justified.

Therapies administered at doses or for conditions that are not supported by recognized compendia or peer‑reviewed evidence are considered investigational and are not covered. This includes use at unsupported dosing regimens or for clinical conditions not listed as medically accepted in standard references.

Coding and Billing

Applicable HCPCS/CPT codesHCPCS

J9312	Injection, rituximab, 10mg.
Q5119	Injection, rituximab-pvvr, biosimilar, (Ruxience), 10mg.
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10mg.
Q5123	Injection, rituximab-arrx, biosimilar, (Riabni), 10mg

Maximum dosing limits (per 10 mg billable unit)

RA maximum dosing (per 10 mg unit)100 units per dose every 14 days x 2 doses in an 18‑week period.

GPA/MPA maximum dosing (per 10 mg unit)Induction: 100 units per dose weekly x 4 doses in a 4‑month period; Initial maintenance: 50 units x 2 doses in a 6‑month period; Subsequent maintenance: 50 units every 6 months.

Pemphigus vulgaris maximum dosing (per 10 mg unit)Initiation: 100 units weekly x 4 doses in a 12‑month period; Maintenance/relapse: 50 units every 16 weeks.

Lupus nephritis & Myasthenia Gravis maximum dosing (per 10 mg unit)100 units per dose every 14 days x 2 doses in a 6‑month period OR 100 units per dose weekly x 4 doses in a 20‑week period.

Multiple sclerosis maximum dosing (per 10 mg unit)100 units every 14 days x 2 doses every 6 months.

Other non‑oncology indications maximum dosing (per 10 mg unit)

Provider Actions, Prior Authorization, and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Rituxan (rituximab) and biosimilars. Coverage is contingent on documentation that the requested use, dosing, and treatment history meet the clinical coverage criteria in this policy. Use outside the stated guidelines or at doses/for indications not recognized as medically accepted (per standard compendia or peer-reviewed literature) is investigational and will be denied as not payable unless an exception is approved.

Prior authorization must document indication, dosing, and that use meets clinical coverage criteria.
Therapies used at doses or for conditions not recognized as medically accepted are investigational and not payable.

Denial Risk

Investigational Use — Denial Risk

Therapies used at a dose or for an indication that is not recognized as a medically accepted use (per AHFS-DI, Micromedex DrugDex, Clinical Pharmacology, Lexi-Drugs, or peer-reviewed published literature) are considered investigational. Neighborhood does not provide coverage for investigational uses—these requests will be denied.

Background and Drug Information

Rituximab is a monoclonal antibody directed against CD20 B‑cells and is used to treat multiple autoimmune conditions listed in the policy (for example, rheumatoid arthritis, granulomatosis with polyangiitis/microscopic polyangiitis, pemphigus vulgaris, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, autoimmune hemolytic anemia, and myasthenia gravis). Common adverse reactions include infusion‑related reactions, cytopenias (e.g., lymphopenia, neutropenia), and infections; the agent carries serious boxed warnings such as progressive multifocal leukoencephalopathy (PML) and other severe reactions. Dosing and administration vary by indication and the policy provides indication‑specific dosing limits and regimens; prior authorization and HBV screening are required before initiation.

Definitions and Safety Information

Rituximab adverse events and boxed warnings

Common adverse reactionsInfusion‑related reactions, fever, lymphopenia, neutropenia, chills, infection, asthenia, nausea, diarrhea, headache, muscle spasms, anemia, peripheral edema.

Serious adverse eventsCytopenias (including neutropenia), serious infections, and progressive multifocal leukoencephalopathy (PML).

Boxed warningsIncludes tumor lysis syndrome, severe mucocutaneous reactions, and PML which can result in death.

Infusion risk managementInfusion‑related reactions are common and should be monitored/managed per product labeling.

Inadequate response (MS context)

Definition of inadequate response (MS)

Policy Revision History

01/01/2020policy_effective

Policy effective date established for Rituxan and biosimilars for non-oncology/non-hematology IV use.

03/02/2023review

Policy reviewed (documented in review history).

12/07/2023review